JP2008535856A5 - - Google Patents

Download PDF

Info

Publication number
JP2008535856A5
JP2008535856A5 JP2008505608A JP2008505608A JP2008535856A5 JP 2008535856 A5 JP2008535856 A5 JP 2008535856A5 JP 2008505608 A JP2008505608 A JP 2008505608A JP 2008505608 A JP2008505608 A JP 2008505608A JP 2008535856 A5 JP2008535856 A5 JP 2008535856A5
Authority
JP
Japan
Prior art keywords
cancer
sema4d
antibody
cells
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008505608A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008535856A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/013174 external-priority patent/WO2006110594A2/en
Publication of JP2008535856A publication Critical patent/JP2008535856A/ja
Publication of JP2008535856A5 publication Critical patent/JP2008535856A5/ja
Pending legal-status Critical Current

Links

JP2008505608A 2005-04-07 2006-04-07 癌の診断、検出および治療におけるsema4d Pending JP2008535856A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66985505P 2005-04-07 2005-04-07
PCT/US2006/013174 WO2006110594A2 (en) 2005-04-07 2006-04-07 Sema4d in cancer diagnosis, detection and treatment

Publications (2)

Publication Number Publication Date
JP2008535856A JP2008535856A (ja) 2008-09-04
JP2008535856A5 true JP2008535856A5 (enExample) 2009-05-07

Family

ID=36997818

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008505608A Pending JP2008535856A (ja) 2005-04-07 2006-04-07 癌の診断、検出および治療におけるsema4d

Country Status (6)

Country Link
US (1) US7919246B2 (enExample)
EP (1) EP1871484A2 (enExample)
JP (1) JP2008535856A (enExample)
AU (1) AU2006235271B2 (enExample)
CA (1) CA2603780A1 (enExample)
WO (1) WO2006110594A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602008004296D1 (de) 2007-02-14 2011-02-17 Vaccinex Inc Humanisierte anti-cd100-antikörper
BRPI0913578A2 (pt) 2008-05-14 2017-06-06 Dermtech Int diagnose de melanoma e lentigo solar por análise de ácido nucléico
EP3320920A1 (en) 2009-05-08 2018-05-16 Vaccinex, Inc. Anti-cd100 antibodies and methods for using the same
EP2766093B1 (en) 2011-10-11 2018-02-21 Vaccinex, Inc. Use of semaphorin-4d binding molecules for modulation of blood brain barrier permeability
CN102584946A (zh) * 2012-03-12 2012-07-18 苏州大学 CaM结合肽及其应用
US9090709B2 (en) 2012-03-28 2015-07-28 Vaccinex, Inc. Anti-SEMA4D antibodies and epitopes
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
SG10201902380SA (en) 2013-06-25 2019-04-29 Vaccinex Inc Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
WO2016179043A1 (en) 2015-05-01 2016-11-10 Dermtech, Inc. Non-invasive skin collection system
US11578373B2 (en) 2019-03-26 2023-02-14 Dermtech, Inc. Gene classifiers and uses thereof in skin cancers
ES2987815T3 (es) 2015-11-13 2024-11-18 Capsa Solutions Llc Una estación de tecnología médica y método de uso
WO2017132541A1 (en) * 2016-01-27 2017-08-03 University Of Maryland, Baltimore A method for monitoring cancer and for regulation of semaphorin 4d to improve cancer immunotherapy regimens
US11976332B2 (en) 2018-02-14 2024-05-07 Dermtech, Inc. Gene classifiers and uses thereof in non-melanoma skin cancers
CN116949097B (zh) * 2023-09-20 2023-12-12 江苏集萃药康生物科技股份有限公司 一种sema4d人源化小鼠模型的构建方法及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576754B2 (en) 1995-11-09 2003-06-10 Dana-Farber Cancer Institute CD100 antigen and uses therefor
US7820447B2 (en) 2000-12-22 2010-10-26 Sagres Discovery Inc. Compositions and methods for cancer
US7171311B2 (en) * 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
US20060194265A1 (en) 2001-10-23 2006-08-31 Morris David W Novel therapeutic targets in cancer

Similar Documents

Publication Publication Date Title
JP2008535856A5 (enExample)
Parkkila et al. The calcium-binding protein S100P in normal and malignant human tissues
JP2009519002A5 (enExample)
JP2008535494A5 (enExample)
CN114599978A (zh) 使用c-met抑制剂治疗癌症患者的方法
JP2006520781A5 (enExample)
JP2008535853A5 (enExample)
RU2013113439A (ru) Идентификация опухолеассоциированных антигенов для диагностики и терапии
CN107532199B (zh) 与间质上皮转化因子抑制剂有关的感受性预测用新型生物标志物及其用途
Xu et al. MiR-548b suppresses proliferative capacity of colorectal cancer by binding WNT2.
CA2807104C (en) Bard1 isoforms in lung and colorectal cancer and use thereof
JP2005520543A5 (enExample)
JP2008535855A5 (enExample)
JP6005272B2 (ja) 胃癌診断及び治療のためのadcy3の用途
WO2009141440A1 (en) Netrin-1 overexpression as a biological marker and a survival factor for aggressive neuroblastoma
JP2008535854A5 (enExample)
EP2649204A2 (en) Novel method of cancer diagnosis and prognosis and prediction of response to therapy
JP2007508020A5 (enExample)
JP2007509612A (ja) Mn/caixおよび癌予後診断
JP2009523004A5 (enExample)
KR102897399B1 (ko) 유방암 진단을 위한 신규 바이오마커
JP2008535491A5 (enExample)
KR102691995B1 (ko) 미만형 위암의 예후 진단 마커
JP2007077155A5 (enExample)
KR102055350B1 (ko) 대장암의 항암제 내성 진단용 바이오마커 및 이의 용도